Moderna, Inc. (MRNA)
Moderna stock soars as hantavirus fears spark outbreak trade
Moderna shares surged on Monday as investors rushed into vaccine and biotech stocks following reports of a hantavirus outbreak linked to a cruise ship, despite health authorities maintaining that the overall public health risk remains low. The stock rose 9.43% to $59.48, its intraday high after a US national tested mildly positive for the Andes strain of hantavirus.
Moderna Stock Jumps. U.S. Passenger on Hantavirus Cruise Ship Tests Positive.
The U.S. health department said one passenger on a repatriation flight has tested mildly positive for the virus, while another is currently experiencing mild symptoms.
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a wider-than-expected net loss and missed earnings estimates due in part to a significant one-time litigation settlement charge. The biotech company generated revenue of $389 million for the quarter, compared with consensus estimates of about $251.8 million.
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook
Moderna (MRNA) delivered a strong 1Q26 revenue beat, driven by international COVID-19 vaccine sales, and reaffirmed 2026 guidance for up to 10% revenue growth. Cost discipline is improving, with R&D and SG&A expenses down meaningfully, but a $0.9B litigation charge led to a wider net loss and negative gross margins. Pipeline momentum is central, with key regulatory catalysts ahead—especially the mRNA-1010 flu vaccine (FDA PDUFA August 5) and oncology assets in late-stage trials.
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $3.02. This compares to a loss of $2.52 per share a year ago.
Moderna Reports Higher Revenue but Posts a Loss
Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets.
Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy
I believe my original bull case on Roivant Sciences has largely played out, with the stock up sharply since my initial coverage. Brepocitinib is clearly now becoming a broader immunology franchise across DM, NIU, CS, and LPP. ROIV also settled with Moderna regarding LNP, which adds to its already cash-rich balance sheet and supports its ongoing buybacks and pipeline.
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Moderna (MRNA) closed at $55.6, indicating a +2.53% shift from the previous trading day.
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
